In this podcast, we are joined by Dr. Andrew Steele, nephrologist at Lakeridge Health. He discusses the efficacy and safety considerations in patients with atrial fibrillation and chronic kidney disease, Canadian recommendations for appropriate dosing of NOACs and how clinicians can limit the progression of renal impairment in their patients. This program was made available through funding from Bayer.

In this podcast, we are joined by Dr. Vineeta Ahooja, cardiologist in the greater Toronto area at the Heart Health Institute, and Dr. George Thanassoulis, cardiologist at McGill University Health Centre and Co-Chair of the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines. They discuss the use of ezetimibe and PCSK9i, including considerations around the costs of medications. When triglycerides are high, should icosapent ethyl or PCSK9i be considered first? Listen to find out! This program was made available through funding from HLS Therapeutics.

Welcome to the podcast series CAN-R3: Canadian Initiative to Reduce Residual Risk – Game Changers in Dyslipidemia Management. In this series, Canadian experts discuss the importance and challenges of reducing LDL-C in patients with established ASCVD, recommendations from the 2021 Canadian Cardiovascular Society Guidelines, and evidence around statins efficacy and adherence in different patient populations. Visit iMedicus.ca/Dyslipidemia to watch the Section 1 accredited webinars.   In this first episode, Dr. Judy Luu and Dr. Shaun Goodman exchange on the different contributors to residual risk, the role of LDL-C in atherosclerosis, the importance of reducing LDL-C as low as possible, identifying patients who benefit the most from intensification therapy beyond statins, and the shift to LDL-C thresholds as opposed to treatment targets.